In a phase II trial in NSCLC patients, delaying the beginning of anti-CTLA-4 therapy tended to prolong PFS and slightly decreased the occurrence of immune-related adverse effects compared to the concurrent combination [140]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.